Biora Therapeutics Inc Ordinary Shares BIOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BIOR is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.64
- Day Range
- $0.63–0.65
- 52-Week Range
- $0.59–6.70
- Bid/Ask
- $0.63 / $0.65
- Market Cap
- $22.66 Mil
- Volume/Avg
- 46,402 / 476,334
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,386.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 58
Comparables
Valuation
|
Metric
|
BIOR
|
RCKT
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 4.34 | 3.27 |
Price/Sales | 2,386.22 | — | 2,031.07 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIOR
|
RCKT
|
VRDN
|
|---|---|---|---|
Quick Ratio | 0.25 | 7.69 | 17.93 |
Current Ratio | 0.30 | 7.80 | 18.26 |
Interest Coverage | −11.68 | −138.48 | −137.76 |
Quick Ratio
BIOR
RCKT
VRDN
Profitability
|
Metric
|
BIOR
|
RCKT
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −140.13% | −38.11% | −42.76% |
Return on Equity (Normalized) | — | −43.04% | −82.42% |
Return on Invested Capital (Normalized) | — | −43.72% | −50.70% |
Return on Assets
BIOR
RCKT
VRDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mmsxcnhct | Kkxr | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wcjmsckm | Jqytpd | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rgrksstcn | Rkkpy | $99.6 Bil | |
MRNA
| Moderna Inc | Qbkykcjn | Yykn | $38.8 Bil | |
ARGX
| argenx SE ADR | Hcxgwwlt | Jsvn | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Ncmnrmpr | Vygx | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wkpjrpjbp | Bjxyt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zycplmcy | Ytklz | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dcwbjhxq | Zhtzq | $12.4 Bil | |
INCY
| Incyte Corp | Tgvrxxxlk | Rmcyz | $11.9 Bil |